Amylyx says FDA grants avexitide Breakthrough Therapy, Orphan Drug status for post-bariatric hypoglycemia
Reuters2026/08/18 11:07- Amylyx plans to submit an FDA New Drug Application for avexitide in post-bariatric hypoglycemia by year-end 2026.
- Phase 3 LUCIDITY met the FDA-agreed primary endpoint, cutting Level 2 and Level 3 hypoglycemic events 55% versus placebo (p=0.000003).
- Avexitide holds FDA Breakthrough Therapy designation, supporting a potential 2027 launch if cleared.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
IMC plans R$ 12 million debenture prepayment on Sept. 15, 2026
Stellar network stablecoin transfer volume increases by 50%, supply decreases by 11.7%
Fund 1 Investments sells 2,256,335 Tilly’s shares worth $9.78 million
The U.S. Treasury market remains overheated! Besent expands repo program, emphasizing "this is not quantitative easing"
U.S. Treasury Secretary Janet Yellen stated on Tuesday that the Treasury's decision last month to expand the buyback program for older-dated U.S. Treasury bonds was mainly aimed at "cooling down" the bond market, which has been heating up recently, and helping the market return to a more balanced state.
Crypto prices
More
